Bevacizumab Augments the Antitumor Efficacy of Infigratinib in Hepatocellular Carcinoma

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma

(2018) Milind Javle et al.   JOURNAL OF CLINICAL ONCOLOGY

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

(2018) Masatoshi Kudo et al.   LANCET

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Infigratinib mediates vascular normalization, impairs metastasis and improves chemotherapy in hepatocellular carcinoma

(2018) Hung Huynh et al.   HEPATOLOGY

Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods

(2018) J. Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study

(2017) Lucia Nogova et al.   JOURNAL OF CLINICAL ONCOLOGY

Fibroblast growth factor receptor 3 isoforms: Novel therapeutic targets for hepatocellular carcinoma?

(2015) Jakob Paur et al.   HEPATOLOGY

Genomic characterization of a large panel of patient-derived hepatocellular carcinoma xenograft tumor models for preclinical development

(2015) Qingyang Gu et al.   Oncotarget

EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma

(2015) et al.   JOURNAL OF HEPATOLOGY

Fibroblast Growth Factor Receptor Inhibitors as a Cancer Treatment: From a Biologic Rationale to Medical Perspectives

(2013) Maria Vittoria Dieci et al.   Cancer Discovery

FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor

(2012) V. Guagnano et al.   Cancer Discovery

Beyond VEGF: Inhibition of the Fibroblast Growth Factor Pathway and Antiangiogenesis

(2011) C. Lieu et al.   CLINICAL CANCER RESEARCH

Brivanib, a Dual FGF/VEGF Inhibitor, Is Active Both First and Second Line against Mouse Pancreatic Neuroendocrine Tumors Developing Adaptive/Evasive Resistance to VEGF Inhibition

(2011) Elizabeth Allen et al.   CLINICAL CANCER RESEARCH

Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase

(2011) Vito Guagnano et al.   JOURNAL OF MEDICINAL CHEMISTRY

Roles of Fibroblast Growth Factor Receptors in Carcinogenesis

(2010) E. M. Haugsten et al.   MOLECULAR CANCER RESEARCH

The Significance of Fibroblast Growth Factor Receptor 2 Expression in Differentiation of Hepatocellular Carcinoma

(2010) Norifumi Harimoto et al.   ONCOLOGY

Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis

(2009) John M.L. Ebos et al.   CANCER CELL

Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis

(2009) Marta Pàez-Ribes et al.   CANCER CELL

Resistance to EGF-R (erbB-1) and VEGF-R modulating agents

(2009) Wolfram C.M. Dempke et al.   EUROPEAN JOURNAL OF CANCER

Hepatocellular Carcinoma Incidence, Mortality, and Survival Trends in the United States From 1975 to 2005

(2009) Sean F. Altekruse et al.   JOURNAL OF CLINICAL ONCOLOGY

AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC)

(2009) Hung Huynh et al.   JOURNAL OF HEPATOLOGY

The FGF family: biology, pathophysiology and therapy

(2009) Andrew Beenken et al.   NATURE REVIEWS DRUG DISCOVERY

Lymphangiogenesis in Esophageal Adenocarcinomas--Lymphatic Vessel Density as Prognostic Marker in Esophageal Adenocarcinoma

(2008) Reda S. Saad et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma

(2008) Hung Huynh et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE

Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer

(2008) Michael Höpfner et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma

(2007) Andrew X. Zhu   CANCER